Pharmacogenetics-Guided Phase i Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

• Main Authors: Soo, R.A, Syn, N, Lee, S.-C, Wang, L, Lim, X.-Y, Loh, M, Tan, S.-H, Zee, Y.-K, Wong, A.L.-A, Chuah, B, Chan, D, Lim, S.-E, Goh, B.-C, Soong, R, Yong, W.-P
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: Nature Publishing Group 2020
• Subjects: antineoplastic agent; capecitabine; thymidylate synthase; adult; aged; breast tumor; cancer staging; clinical protocol; clinical trial; colorectal tumor; dose calculation; enhancer region; female; genetic polymorphism; genetics; genotype; human; male; maximum tolerated dose; metastasis; middle aged; multicenter study; pathology; pharmacogenetic testing; phase 1 clinical trial; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Protocols; Colorectal Neoplasms; Drug Dosage Calculations; Enhancer Elements, Genetic; Female; Genotype; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pharmacogenomic Testing; Polymorphism, Genetic; Thymidylate Synthase
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/182460
• Institution: National University of Singapore

10.1038/srep27826